The Food and Drug Administration (FDA) has further expanded the U.S. indications of Novo Nordisk’s (NVO) popular weight loss ...

Wegovy® (semaglutide) injection 2.4 mg is now indicated to treat adults with metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver ...

Novo Nordisk A/S (NYSE: NVO) is one of the top cheap stocks that will go to the moon according to Reddit. On August 13, BNP Paribas Exane upgraded Novo Nordisk A/S (NYSE:NVO) to Neutral from ...

Novo Nordisk said on Friday the U.S. Food and Drug Administration had granted accelerated approval for its weight-loss drug ...

On Thursday, Eli Lilly and Co. (NYSE:LLY) said it will sharply increase the list price of its weight-loss and type 2 diabetes ...

Novo Nordisk’s obesity drug Wegovy was cleared by U.S. regulators to treat an increasingly common liver disease, MASH.

The new approval allows the GLP-1 to be used to treat adults with the liver disease metabolic dysfunction-associated steatohepatitis (MASH) and liver scarring. Wegovy is the first GLP-1 to receive ...

It seems to be holding off on price adjustments demanded by President Trump.

Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases.

The integration aims to simplify access to Zepbound for eligible members while providing comprehensive, whole-person care to ...

A growing wave of lawsuits is targeting Novo Nordisk, the manufacturer of the widely used drugs Ozempic and Wegovy, following ...